Magnesium in Acute Myocardial Infarction (The Mami Study): Effect of Early Versus Late Magnesium Administration on CK-Levels

  • H. G. Stuehlinger
  • W. Behringer
  • W. Hoedl
  • D. Seidler
  • A. Zeiner
  • W. Schoerkhuber
  • A. AN. Laggner


Introduction: Two major studies have evaluated intravenous magnesium in patients with acute myocardial infarction. LIMIT-2 found a 24% reduction of mortality (day 28) in the magnesium treated group. However, ISIS-4 demonstrated no such benefit on mortality (day 35). In LIMIT-2, patients were started on intravenous magnesium immediately after admission, in contrast to ISIS-4, where magnesium was administered later.

Hypothesis: The beneficial effect of magnesium in acute myocardial infarction (AMI) depends upon early administration of the drug.

Methods: 102 patients undergoing thrombolysis (rt-PA) for acute myocardial infarction were randomised to receive magnesium at two different times. In group 1 the magnesium infusion was started concurrent with thrombolysis, group 2 received magnesium 3 hours later. Total dose of magnesium was 72 mmol (bolus of 8 mmol, followed by a continous infusion for 22.5 hours at a rate of 3.2 mmol/h).

Results: Maximum Ck levels (Ck max.) in group 1 were higher than in group 2 (1126 vs. 911 U/l) and reached the peak earlier (9.6 vs. 10.5 hours). In patients with anterior wall infarction these trends are more destinct: in group 1 (n=23) and 2 (n=21) Ck max. was 1598 U/l and 1241 U/l respectively. Group 1 reached these levels after 8.3 hours as opposed to 9 hours for group 2. A subgroup analysis was performed on patients with documented reperfusion (ECG: 70% reduction of initial ST-elevation after 3 hours). These patients had a Ck max. of 1694 U/l if magnesium had been started early (group 1) and 1209 U/l in group 2. These differences did not reach statistical significance.

Conclusion: Early administration of magnesium in AMI leads to higher and earlier maximum Ck levels which might indicate earlier and more pronounced reperfusion. The results of the MAMI study presented above might elucidate the divergent results of LIMIT-2 and ISIS-4.


Acute Myocardial Infarction Acute Myocardial Infarction Magnesium Sulfate Magnesium Sulphate Intravenous Magnesium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Heesch CM, Eichhorn EJ. (1994); Magnesium in acute myocardial infarction. Ann Emerg Med, 24: 1154–1160.CrossRefGoogle Scholar
  2. 2.
    Zwillinger L (1935). Über die Magnesiumwirkung auf das Herz. Klin Wochenschr, 14: 1429–1433.CrossRefGoogle Scholar
  3. 3.
    Elek SR, Katz LN. (1942) Further observations on the action of drugs on coronary vessel caliber: paredrine, angiotonin, renin, quinidine, insulin, magnesium sulphate, morphine, acid and alkali. J Pharm Exptl Therap; 75: 178.Google Scholar
  4. 4.
    Boyd LJ, Scherf D. (1943) Magnesium sulfate in paroxysmal tachycardia. Am J Med Sei; 206: 43.CrossRefGoogle Scholar
  5. 5.
    Hoffmann L, Siegel R. (1952); Die Behandlung von Kreislaufstörungen mit Magnesiumverbindungen. Hippocrates 23: 387–390.Google Scholar
  6. 6.
    Malkiel-Shapiro B, Bersohn I, Terner PE. (1956) Parenteral magnesium sulphate therapy. Med Proc; 2: 455–462.Google Scholar
  7. 7.
    Malkiel-Shapiro B. (1958) Further observations on parenteral magnesium sulphate therapy in coronary heart disease: A clinical appraisal. South Afr Med J; 32: 1211–1215.Google Scholar
  8. 8.
    Parsons RS, Butler TL, Seilars EP. (1960) Coronary artery disease. Med Proc; 6: 479.Google Scholar
  9. 9.
    Bajusz E, Selye H. (1959) Conditioning factors for cardiac necroses. Trans NY Acad Sei; 21: 659–667.Google Scholar
  10. 10.
    Bajusz E, Selye H. (1960) The chemical prevention of cardiac necroses following occlusion of coronary vessels. Can Med Assoc J; 82: 212–213.Google Scholar
  11. 11.
    Morton BC, Nair RC, Smith FM, McKibbon TG, Poznanski WJ. (1984) Magnesium therapy in acute myocardial infarction - a double blind study. Magnesium; 3: 346–352.Google Scholar
  12. 12.
    Smith LF, Heagerty AM, Bing RF, Barnett DB. (1986) Intravenous infusion of magnesium sulfate after myocardial infarction: effects on arrhythmias and mortality. Int J Cardiol, 12: 175–180.CrossRefGoogle Scholar
  13. 13.
    Abraham AS, Rosenmann D, Kramer M, Balkin J, Zion MM, Farbstien H: (1987) Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med; 147: 753–755.CrossRefGoogle Scholar
  14. 14.
    Rasmussen HS, Gronbaek M, Cintin C, Balslov S, Norregard P, McNair P. (1988) One-year death rate in 270 patients with suspected acute myocardial infarction, initially treated with intravenous magnesium or placebo. Clin Cardiol, 11: 377–381.CrossRefGoogle Scholar
  15. 15.
    Ceremuzynski L, Jurgiel R, Kulakoswski P, Gebalska J. (1989) Threatening arrhythmias in acute myocardial infarction are prevented by intravenous magnesium sulfate. Am Heart J; 118: 1333–1334.CrossRefGoogle Scholar
  16. 16.
    Shechter M, Hod H, Marks N, Behar S, Kaplinsky E, Rabinowitz B. (1990) Magnesium therapy and mortality in acute myocardial infarction. Am J Cardiol, 66: 271–274.CrossRefGoogle Scholar
  17. 17.
    Feldstedt M, Boesgaard S, Bouchelouche P, Svenningsen A, Brooks L, Lech Y, Aldershvile J, Skagen K, Godtfredsen J. (1991) Magnesium-substitution in acute ischaemic heart syndroms. Eur Heart J; 12: 1215–1218.CrossRefGoogle Scholar
  18. 18.
    Teo KK, Yusuf S, Collins R, Held PH, Peto R. (1991) Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. Br Med J; 303: 1499–1503.CrossRefGoogle Scholar
  19. 19.
    Antman EM. (1995) Randomized Trials of Magnesium in Acute Myocardial Infarction: Big Numbers Do Not Tell the Whole Story. Am J Cardiol, 75: 391–393.CrossRefGoogle Scholar
  20. 20.
    Woods KL, Fletcher S, Roffe Ch, Haider Y. (1992) Intravenous magnesium sulphate in suspected acute myocardial infarction: result of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet; 339: 1553–1558.CrossRefGoogle Scholar
  21. 21.
    ISIS-4 (1995) Collaborative Group. A randomised factorial trial assessing early oral Captopril, oral nitrate, and intravenous magnesium sulphate in 58.050 patients with suspected acute myocardial infarction. Lancet, 345: 669–682.CrossRefGoogle Scholar
  22. 22.
    Beuckelmann DJ. Editorial: (1994) Magnesiumtherapie bei Myocardinfarkt: Bei differenzierter Indikation sinnvoll. Münch Med Wschr; 136: 34.Google Scholar
  23. 23.
    Du Toit EF, Opie LH. (1992) Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium tlux at reperfusion. Circ Res; 70: 960–967.Google Scholar
  24. 24.
    Opie LH. (1994) Myocardial stunning - are calcium antagonists useful? Cardiovasc Drugs Ther; 8: 533–541.CrossRefGoogle Scholar
  25. 25.
    Lüderitz B, Manz M. (1994) Die Bedeutung von Magnesium in der Intensivmedizin. Z Kardiol; Suppl 6: 121–124.Google Scholar
  26. 26.
    Seelig MS, Elin RJ. (1995) Reexamination of magnesium infusions in myocardial infarction. Am J Cardiol, 76: 172–173.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • H. G. Stuehlinger
    • 1
  • W. Behringer
    • 1
  • W. Hoedl
    • 1
  • D. Seidler
    • 1
  • A. Zeiner
    • 1
  • W. Schoerkhuber
    • 1
  • A. AN. Laggner
    • 1
  1. 1.Dept. of Emergency MedicineUniv. Hospital ViennaViennaAustria

Personalised recommendations